Effect of Empagliflozin on Endothelial Function in Cardiovascular High Risk Diabetes Mellitus: Multi-Center Placebo-Controlled Double-Blind Randomized Trial
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Empagliflozin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMBLEM
- 29 Sep 2021 Results of a post hoc analysis presented at the Hypertension Scientific Session 2021
- 29 Jun 2021 Results of post hoc analysis (n=105) assessing the effect of empagliflozin on estimated fluid volumes in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association.